北京天智航医疗科技股份有限公司 2025年度业绩预告

Core Viewpoint - The company anticipates significant revenue growth for 2025, but expects to incur larger losses compared to the previous year, primarily due to reduced investment income and increased expenses related to stock incentive plans [3][6]. Group 1: Performance Forecast - The company forecasts 2025 revenue between 270 million and 300 million yuan, representing a year-on-year growth of 50.97% to 67.75% [3]. - The net loss attributable to the parent company is expected to be between 165 million and 198 million yuan, an increase in loss of 43.87 million to 76.87 million yuan compared to the previous year, which translates to an increase of 36.22% to 63.46% [3]. - The net loss after deducting non-recurring gains and losses is projected to be between 200 million and 233 million yuan, with an increase in loss of 30.25 million to 63.25 million yuan compared to the previous year, reflecting an increase of 17.82% to 37.26% [3]. Group 2: Previous Year Performance - In the previous year (2024), the company reported revenue of 178.84 million yuan and a net loss of 121.13 million yuan [5]. - The net loss after deducting non-recurring gains and losses was 169.74 million yuan [5]. Group 3: Reasons for Performance Changes - The significant revenue growth is attributed to a recovering market environment and increased sales and technical service income [6]. - The widening net loss is primarily due to a substantial decrease in investment income, increased stock incentive plan expenses, and higher income tax expenses resulting from the reversal of deferred tax assets from prior years, which collectively contributed to an increase in losses of approximately 89 million yuan [6]. Group 4: Other Information - The company has performed over 49,000 surgeries using its orthopedic surgical robot during the reporting period, with a cumulative total exceeding 150,000 surgeries by the end of the reporting period [8].